Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic
Albert Garcia‐Romeu, David J. Cox, Kirsten E. Smith, et al.
Drug and Alcohol Dependence (2020) Vol. 208, pp. 107849-107849
Open Access | Times Cited: 144

Showing 1-25 of 144 citing articles:

An update on the clinical pharmacology of kratom: uses, abuse potential, and future considerations
Christopher R. McCurdy, Abhisheak Sharma, Kirsten E. Smith, et al.
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 2, pp. 131-142
Closed Access | Times Cited: 18
Epidemiology of New Psychoactive Substances in Relation to Traditional Drugs of Abuse in Clinical Oral Fluid Samples
Magnus Axelsson, Hanna Lövgren, Robert Kronstrand, et al.
Basic & Clinical Pharmacology & Toxicology (2025) Vol. 136, Iss. 2
Open Access | Times Cited: 2
Prevalence and description of kratom (Mitragyna speciosa) use in the United States: a cross‐sectional study
Jonathan Schimmel, Elise Amioka, Karilynn Rockhill, et al.
Addiction (2020) Vol. 116, Iss. 1, pp. 176-181
Closed Access | Times Cited: 99
Therapeutic benefit with caveats?: Analyzing social media data to understand the complexities of kratom use
Kirsten E. Smith, Jeffrey M. Rogers, Destiny Schriefer, et al.
Drug and Alcohol Dependence (2021) Vol. 226, pp. 108879-108879
Open Access | Times Cited: 55
Understanding Kratom Use: A Guide for Healthcare Providers
Marc T. Swogger, Kirsten E. Smith, Albert Garcia‐Romeu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 52
Kratom use as more than a “self-treatment”
Kirsten E. Smith, Kelly E. Dunn, Jeffrey M. Rogers, et al.
The American Journal of Drug and Alcohol Abuse (2022) Vol. 48, Iss. 6, pp. 684-694
Closed Access | Times Cited: 37
Ecological Momentary Assessment of Self-Reported Kratom Use, Effects, and Motivations Among US Adults
Kirsten E. Smith, Leigh V. Panlilio, Jeffrey D. Feldman, et al.
JAMA Network Open (2024) Vol. 7, Iss. 1, pp. e2353401-e2353401
Open Access | Times Cited: 14
Kratom safety and toxicology in the public health context: research needs to better inform regulation
Jack E. Henningfield, Oliver Grundmann, Marilyn A. Huestis, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 11
Prevalence of Kratom Use Disorder Among Kratom Consumers
Katherine Hill, Oliver Grundmann, Kirsten E. Smith, et al.
Journal of Addiction Medicine (2024) Vol. 18, Iss. 3, pp. 306-312
Closed Access | Times Cited: 9
Kratom addiction per DSM-5 SUD criteria, and kratom physical dependence: Insights from dosing amount versus frequency
Jeffrey M. Rogers, Stephanie T. Weiss, David H. Epstein, et al.
Drug and Alcohol Dependence (2024) Vol. 260, pp. 111329-111329
Closed Access | Times Cited: 9
Lyophilized Kratom Tea as a Therapeutic Option for Opioid Dependence
Lisa Wilson, Hannah M. Harris, Shainnel O. Eans, et al.
Drug and Alcohol Dependence (2020) Vol. 216, pp. 108310-108310
Closed Access | Times Cited: 52
Searching for a Signal: Self-Reported Kratom Dose-Effect Relationships Among a Sample of US Adults With Regular Kratom Use Histories
Kirsten E. Smith, Jeffrey M. Rogers, Kelly E. Dunn, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 36
Assessment of Kratom Use Disorder and Withdrawal Among an Online Convenience Sample of US Adults
Kirsten E. Smith, Kelly E. Dunn, Jeffrey M. Rogers, et al.
Journal of Addiction Medicine (2022) Vol. 16, Iss. 6, pp. 666-670
Open Access | Times Cited: 32
Exploring the self-reported motivations of kratom (Mitragyna speciosa Korth.) use: a cross-sectional investigation
Oliver Grundmann, Charles A. Veltri, Diana Morcos, et al.
The American Journal of Drug and Alcohol Abuse (2022) Vol. 48, Iss. 4, pp. 433-444
Closed Access | Times Cited: 31
Examining the paradoxical effects of kratom: a narrative inquiry
Kirsten E. Smith, Jeffrey D. Feldman, Kelly E. Dunn, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 20
Clinical Assessment of the Drug Interaction Potential of the Psychotropic Natural Product Kratom
Rakshit S. Tanna, James Nguyen, Deena L. Hadi, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 113, Iss. 6, pp. 1315-1325
Open Access | Times Cited: 18
Growing pains with kratom: experiences discussed in subreddits contrast with satisfaction expressed in surveys
Jeffrey M. Rogers, Kayla Colvin, David H. Epstein, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 6
Effects of Itraconazole on Pharmacokinetics of Mitragynine and 7-Hydroxymitragynine in Healthy Volunteers
Pooja Mongar, Amit Jaisi, Thammasin Inkviya, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 3, pp. 823-833
Open Access | Times Cited: 5
Effects of kratom alkaloids on mesolimbic dopamine release
James P Manus, Rebecca C Crenshaw, Lindsay C Ringer, et al.
Neuroscience Letters (2025), pp. 138153-138153
Closed Access
Evaluation of the Mitragynine Content, Levels of Toxic Metals and the Presence of Microbes in Kratom Products Purchased in the Western Suburbs of Chicago
Walter C. Prozialeck, Joshua R. Edwards, Peter C. Lamar, et al.
International Journal of Environmental Research and Public Health (2020) Vol. 17, Iss. 15, pp. 5512-5512
Open Access | Times Cited: 40
Social, psychological, and substance use characteristics of U.S. adults who use kratom: Initial findings from an online, crowdsourced study.
Kirsten E. Smith, Kelly E. Dunn, Oliver Grundmann, et al.
Experimental and Clinical Psychopharmacology (2021) Vol. 30, Iss. 6, pp. 983-996
Open Access | Times Cited: 39
When an obscurity becomes trend: social-media descriptions of tianeptine use and associated atypical drug use
Kirsten E. Smith, Jeffrey M. Rogers, Justin C. Strickland, et al.
The American Journal of Drug and Alcohol Abuse (2021) Vol. 47, Iss. 4, pp. 455-466
Open Access | Times Cited: 36
Site selective C–H functionalization of Mitragyna alkaloids reveals a molecular switch for tuning opioid receptor signaling efficacy
Srijita Bhowmik, Juraj Galeta, Václav Havel, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 32
A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans
Elisabeth Prevete, Kim P. C. Kuypers, Eef L. Theunissen, et al.
Human Psychopharmacology Clinical and Experimental (2021) Vol. 37, Iss. 1
Open Access | Times Cited: 32
Kratom Abuse Potential 2021: An Updated Eight Factor Analysis
Jack E. Henningfield, Daniel W. Wang, Marilyn A. Huestis
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top